Search

A recent study conducted by investigators at Harvard Medical School has found that current clinical criteria for identifying anaphylaxis in infants and toddlers may not accurately account for their unique presentation. The researchers developed modified criteria for identifying anaphylaxis in young children and compared them to the widely used 2006 National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network (NIAID/FAAN) criteria. The modified criteria captured 98% of patient encounters, compared to 85% captured by the NIAID/FAAN criteria. The study suggests that the modified criteria may improve the identification of anaphylaxis in infants and potentially toddlers, but further research is needed to validate these findings. [Extracted from the article]

A recent study conducted by researchers at Mayo Clinic in Scottsdale, Arizona, examined the incidence and risk factors for pediatric perioperative anaphylaxis (pPOA) in the United States. The study analyzed data from the US Nationwide Inpatient Sample from 2005 to 2014 and identified 297 cases of pPOA out of 3,601,180 surgeries and procedures in children aged 0-18 years. The study found that age, procedure type, and comorbidities were significant risk factors for pPOA. The research concluded that pPOA is a serious and potentially life-threatening condition that requires further attention and prevention strategies. [Extracted from the article]

A recent report from Memorial Sloan-Kettering Cancer Center discusses the use of omalizumab, an anti-IgE monoclonal antibody, for the treatment of urticaria (hives) related to anti-GD2 immunotherapy. Urticaria is a common side effect of this type of immunotherapy, and refractory cases can negatively impact patients' quality of life and treatment. The study found that omalizumab effectively managed refractory urticaria in two patients, allowing them to continue with anti-GD2 immunotherapy without impacting its effectiveness. This research provides valuable insights into the management of urticaria in the context of cancer treatment. [Extracted from the article]

The article focuses on a clinical trial assessing the safety, tolerability, and pharmacokinetics of PF-07832837 in both healthy adults and patients with moderate to severe atopic dermatitis. Topics include evaluating drug safety; analyzing pharmacokinetics and pharmacodynamics; and monitoring effects on atopic dermatitis symptoms.

The article discusses the research from Johns Hopkins School of Medicine, which highlights fexofenadine (FEX) as an effective treatment for allergic rhinitis and urticaria, providing fast symptom relief and a long-lasting effect without causing drowsiness. Clinical trials confirm that FEX offers significant quality-of-life improvements with a favorable safety profile.

The article highlights a study from Calcutta National Medical College evaluating tofacitinib for chronic spontaneous urticaria (CSU) resistant to antihistamines. Topics include the significant improvement in urticaria activity and disease control in patients treated with tofacitinib, the study's design, and the need for further research.

A case report from the University of Ljubljana in Slovenia discusses the management of immediate hypersensitivity reactions in a patient with phenylketonuria (PKU) who was receiving pegvaliase treatment. PKU is a metabolic disorder characterized by elevated levels of phenylalanine. Pegvaliase is an enzyme replacement therapy used to reduce phenylalanine concentration, but it can cause severe hypersensitivity reactions. The patient experienced an acute hypersensitivity reaction after discontinuing antihistamine therapy, but the reaction was successfully managed by reintroducing antihistamines and scheduling their administration closer to the pegvaliase injection. This approach allows PKU patients to continue benefiting from pegvaliase therapy. [Extracted from the article]

A recent study conducted by researchers at Rocky Vista University College of Osteopathic Medicine has shed light on the rare occurrence of amiodarone-induced anaphylaxis. The study found that there have been a total of 10 reported cases of this type of anaphylaxis, with the majority of patients being male and ranging in age from 15 to 86 years old. The trigger for anaphylaxis was typically intravenous injection of amiodarone, and symptoms included hypotension, bronchospasm or skin rash, angioedema, and unconsciousness. Prompt treatment with epinephrine, norepinephrine, antihistamines, or steroids was crucial for patient recovery. The study suggests that solvent polysorbate 80, amiodarone, and iodide may contribute to the development of amiodarone-induced anaphylaxis. [Extracted from the article]

The patent application titled "Dosing for Anti-Tryptase Antibodies" discusses a method of treating chronic spontaneous urticaria (CSU) using anti-tryptase beta antibodies. CSU is a condition characterized by hives and swelling that lasts for at least six weeks without an obvious cause. The method involves administering the antibody to patients with refractory CSU who have not responded to antihistamines. The application includes information on dosing regimens, cycles, and the specific amino acid sequences of the antibody. Improved therapies for CSU are still being sought. [Extracted from the article]

Researchers at the College of Health Sciences have conducted a study on refractory anaphylaxis, a severe and unpredictable hypersensitivity response that affects multiple organs. The study aimed to evaluate the association between platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) levels and refractory anaphylaxis. The researchers analyzed medical records of 118 adults with anaphylaxis and found that patients with refractory anaphylaxis had significantly elevated PLR and NLR levels compared to non-refractory anaphylaxis patients. The study concluded that elevated PLR and NLR serve as independent indicators significantly associated with refractory anaphylaxis. [Extracted from the article]

The article reports on the commendation made by De Motu Cordis (DMC) on the U.S. Food and Drug Administration (FDA) approval of ARS Pharma's Neffy, the first-ever needle-free intranasal epinnephrine delivery device for the treatment of anaphylaxis. Topics discussed include significance of the approval, comments from Professor John Fraser, founder, chief medical officer (CMO), and director at DMC, and background of DMC.

A recent study conducted by researchers at the Medical University of Silesia in Katowice, Poland, aimed to determine if certain biomarkers could predict the response to omalizumab treatment for chronic spontaneous urticaria (CSU). The study analyzed the eosinophil/neutrophil/platelet/basophil-to-lymphocyte ratio (ELR, NLR, PLR, BLR) in CSU patients before and after six months of omalizumab treatment. The results showed that these ratios did not significantly change during the treatment period and were not useful in predicting the efficacy of omalizumab. The study also found correlations between certain biomarkers and initial levels of tIgE, anti-TPO/IgE ratio, and CRP. [Extracted from the article]

Researchers at Guangzhou University of Chinese Medicine have conducted a study on the potential toxicity of the environmental pollutant butyl hydroxyanisole (BHA) and its role in chronic urticaria (CU). Using various databases, the researchers identified 81 potential targets of BHA-induced CU, with 31 core targets involved in cancer signaling, estrogen, and endocrine resistance pathways. Molecular docking confirmed the ability of BHA to bind with these core targets. The study provides insights into the molecular mechanisms of BHA toxicity and its association with CU, which can contribute to the prevention and treatment of chronic urticaria caused by environmental BHA exposure. [Extracted from the article]

A recent report discusses research findings on chronic spontaneous urticaria (CSU), a common and distressing skin disease characterized by itchy wheals and angioedema. The report highlights that there is currently no cure for CSU and that symptomatic treatment is often insufficient. Omalizumab, a humanized anti-immunoglobulin E monoclonal antibody, is currently the only licensed biological drug for CSU. However, recent advances in the understanding of the disease's pathophysiological mechanisms have led to the investigation of several other potential treatments, including biologicals and small molecules. The report provides an overview of current and future therapeutic options for CSU based on the known pathogenesis of the disease. [Extracted from the article]

A recent study from Hospital Braga in Portugal focuses on a case of anaphylaxis induced by intravenous hydrocortisone. The patient, a 34-year-old pregnant woman with a history of allergic rhinitis, developed an allergic reaction after receiving hydrocortisone for postpartum pain management. The patient was treated with adrenaline and antihistamines and was diagnosed with anaphylactic reaction to group A corticosteroids. The study highlights the importance of being aware of corticosteroid allergies and providing safe alternatives for patients who demonstrate tolerance to other corticosteroids. [Extracted from the article]

A recent study conducted by researchers at Strasbourg University Hospital in France explores the role of oxidative stress and mitochondria in anaphylaxis and mast cell degranulation. Anaphylaxis is a severe allergic reaction that can lead to anaphylactic shock. The study found that oxidative stress and mitochondrial dysfunction play a crucial role in mast cell degranulation, which is a key process in anaphylaxis. The researchers suggest that targeting oxidative stress and mitochondria could be a potential therapeutic approach for treating anaphylaxis and reducing its harmful effects. [Extracted from the article]

A recent study conducted at Fu Jen Catholic University in Taipei, Taiwan, has found that prior bariatric surgery is associated with a lower risk of life-threatening complications and prolonged hospital stays in patients admitted for acute allergic reactions and anaphylaxis. The study analyzed data from the US Nationwide Inpatient Sample database from 2005 to 2018 and found that patients who had undergone bariatric surgery had significantly lower rates of respiratory distress, pneumonia, sepsis, intubation, and unfavorable discharge compared to those who had not undergone the surgery. The researchers suggest that further prospective studies are needed to confirm these findings and explore the underlying mechanisms. [Extracted from the article]

The article offers information on a study by Genentech Inc. investigating the impact of angioedema on the effectiveness of omalizumab in treating chronic spontaneous urticaria (CSU). Topics discussed include the comparative efficacy of omalizumab with and without angioedema; the dose-dependent response of omalizumab in CSU patients; and recommendations for initial treatment protocols.

The article offers information on the effectiveness of a rapid response mobile application in enhancing clinical performance during simulated care events. Topics discussed include the improvement in medication ordering times for anaphylaxis and supraventricular tachycardia; the overall performance of interns using the application; and the usability feedback from participants.

A recent report from researchers at the University of Kentucky College of Medicine discusses the treatment options for patients with platinum resistant epithelial ovarian cancer who also experience hypersensitivity reactions to paclitaxel, a commonly used medication. The researchers explored the use of mirvetuximab soravtansine-gynx (MIRV), a folate receptor alpha (FRa) directed antibody and microtubule inhibitor, as an alternative treatment option. They presented a case study of a 33-year-old female patient with a history of severe anaphylaxis to paclitaxel who was successfully treated with MIRV after careful monitoring. The researchers concluded that although there is a theoretical risk of cross reactivity between paclitaxel and MIRV, patients with a history of severe hypersensitivity to paclitaxel could potentially be treated with MIRV under careful monitoring. [Extracted from the article]

A study conducted at the University of Hong Kong has validated the traditional Chinese version of the Urticaria Control Test (UCT) among Chinese chronic urticaria (CU) patients in Hong Kong. The study found that the Chinese UCT showed excellent internal consistency, test-retest reliability, construct validity, convergent validity, known-group validity, and sensitivity to change. The researchers concluded that the traditional Chinese UCT is a valid, reliable, and sensitive-to-change instrument for measuring disease control among Hong Kong Chinese with CU. This information may be useful for individuals researching urticaria and seeking patient-reported outcome measures for disease control. [Extracted from the article]

A recent study conducted by researchers at Wroclaw Medical University in Poland aimed to assess the serum concentration of interleukin-5 receptor (IL-5R) in relation to disease activity and pruritus intensity in adult patients with atopic dermatitis (AD) and chronic spontaneous urticaria (CSU). The study included 45 participants, with 15 patients in each group (AD, CSU, and healthy controls). The results showed that the IL-5R concentration was significantly higher in patients with CSU compared to patients with AD and the control group. However, there was no correlation between IL-5R levels and disease severity or pruritus intensity. The researchers concluded that while IL-5R may play a functional role in the pathogenesis of these diseases, it may not be fully useful in reflecting symptom severity. Further studies with larger patient cohorts are needed to confirm these findings. [Extracted from the article]

A report from the Gazi University Faculty of Medicine in Ankara, Turkey discusses two cases of anaphylaxis in children following bone marrow transplantation. Anaphylaxis is a severe allergic reaction that can occur during hematopoietic stem cell transplantation, a treatment for various diseases. The researchers suggest that the anaphylactic reactions may have been triggered by cryoprotective agents used in the transplantation process, such as dimethyl sulfoxide. However, they also acknowledge that other components of the stem cell products could have played a role. Further research is needed to better understand and prevent these reactions. [Extracted from the article]

A recent report from Milan, Italy discusses the case of a 2-year-old boy with chronic neurovisceral acid sphingomyelinase deficiency (ASMD) who experienced hypersensitivity reactions to the drug olipudase alfa. The boy underwent a desensitization protocol with a gradual dose escalation, which allowed him to reach a therapeutic dose without adverse reactions. However, during the second administration of a higher dose, the boy experienced another adverse reaction, suggesting the need for a different desensitization strategy. This case highlights the importance of customizing desensitization protocols for individual patients and raises questions about achieving therapeutic targets in sensitive children. [Extracted from the article]

Researchers at Xi'an Jiaotong University in China have conducted a study on anaphylaxis, a severe allergic reaction. The study focused on the activation of mast cells, which play a role in allergic reactions, by a metabolite called N-demethylsinomenine (M-3) and its prototype sinomenine. The researchers found that M-3 can activate mast cells synergistically with sinomenine, exacerbating anaphylaxis. These findings provide important insights into drug safety. [Extracted from the article]